Background: An understanding of the current status of patients with type 1 diabetes mellitus (T1DM) can help to provide appropriate treatment. Methods: This was a retrospective analysis of the DIabetes Versorgungs-Evaluation (DIVE) and the Diabetes-Patienten-Verlaufsdokumentation (DPV) databases for Germany. Results: The analysis included 56,250 people with T1DM (54.2% male), a median age of 36.8 years, and a median diabetes duration of 12.4 years. 15.3% were obese (body mass index ≥ 30kg/m 2 ). Long-acting insulin analogs were used by 53.3%, short-acting analogs by 72.1%, and oral antidiabetic drugs by 4.7%. Patients had a median glycosylated hemoglobin (HbA1c) of 7.8%. There was a drop in HbA1c and an increase in the rate of hypertension, oral antidiabetic drug use, and in the rate of severe hypoglycemia (all p < 0.01) with age. Flash glucose monitoring (FGM) showed the best glucose values with fewer complications compared to other monitoring systems. HbA1c and FBG were lower in patients using a pump versus multiple daily injections (MDIs; 7.7 versus 7.9% and 7.8 versus 8.7 mmol/l; all adjusted p < 0.01). Patients had a lower risk of at least one severe hypoglycemic or DKA episode during the most recent treatment year with pump treatment compared to MDI (9.4% versus 10.5% and 4.7% versus 6.1%, both adjusted p < 0.01).
Introduction
The incidence of type 1 diabetes mellitus (T1DM) is increasing worldwide. 1, 2 In Europe, the incidence rate of childhood T1DM is rising by 3-4% per annum, 3, 4 with 28,200 children newly diagnosed in 2017. 4 Individuals with T1DM have an increased risk of cardiovascular (CV) disease and a reduced life expectancy compared with the general population. [5] [6] [7] [8] T1DM adversely affects health-related quality of life, daily physical activities and work productivity, and is associated with increased use of medical resources. 9 Intensive therapy can reduce the risk of microvascular and macrovascular complications associated with T1DM. 10, 11 A clear understanding of the current status and characteristics of individuals with T1DM can help medical practitioners provide appropriate treatment and facilitate the development of strategies to improve the care of patients with T1DM. The aim of the current study was to characterize patient, disease, and treatment characteristics of a large cohort of adults with T1DM from within the DIabetes Versorgungs-Evaluation (DIVE) and Diabetes-Patienten-Verlaufsdokumentation (DPV) databases (Austria, Germany, Luxemburg, Switzerland) and to explore the balance of benefits (e.g. HbA1c) and risks [hypoglycemia, diabetic ketoacidosis (DKA)] of treatment in this patient population.
Methods

Study design and data sources
Data were obtained from the DIVE registry and the DPV database, which were combined for this analysis.
The DIVE registry was established in Germany in 2011. 12 Consecutive patients with diabetes mellitus, regardless of their disease stage and treatment strategy, were enrolled at 152 outpatient clinics across the country. Data were entered into the database using DIAMAX (axaris -software & systeme GmbH) or DPV software. The protocol was approved by the ethics committee of the Medical School of Hannover, Germany on 25 August 2011 (no. 6003), and all patients included in the DIVE registry provided written informed consent.
The DPV database was established in 1995. 13 A total of 424 centers in Germany, Austria, Switzerland, and Luxemburg contributed data. Every 6 months, data on patients with diabetes mellitus are prospectively documented using the DPV software and the anonymized data are sent to the University of Ulm, Ulm, Germany. The DPV initiative was approved by the ethics committee of the University of Ulm on 14 August 2009 (no. 202/09), and data collection was approved by local review boards. All patients gave their written consent prior to enrolment in the registry.
For the current analysis, only adult patients from Germany with T1DM, aged 18 years or more, who were registered between 2000 and 2017, including information on their pharmacotherapy, were included ( Figure 1 ). Patients with 'latent autoimmune diabetes in adults' were excluded. Hypertension definition was based on blood pressure levels >140 mmHg systolic or >90 mmHg diastolic or receiving antihypertensive drugs (or any combination of these) which can be considered conservative in patients with diabetes. A sedentary lifestyle was defined as performing physical activity less than once a week. Coronary artery disease was defined as prior myocardial infarction (MI) or angina pectoris. A cardiovascular event was defined as prior MI or stroke. HbA1C values were standardized to the Diabetes Control and Complications Trial (DCCT) reference range (20-42 mmol/mol; 4.05-6.05%). Therefore, the multiple of the mean transformation method was used. 14 In line with previous DIVE/DPV analyses, hypoglycemia with coma was defined as a loss of consciousness or an occurrence of seizures. 15 For severe hypoglycemia, the definition of the American Diabetes Association Workgroup on Hypoglycemia was used: 'an event requiring assistance by another person to actively administer carbohydrates, glucagon, or other resuscitative actions.' 16 
Documentation
Statistics
Data from all patients were combined and analyzed as a single data set. For each patient, data of the most recent treatment year in the period 2000-2017 were aggregated (median) before analysis. For current therapy, information prior to the most recent visit was used. Patients documented in both databases (DIVE and DPV) were only included once in the analysis. Descriptive analyses were conducted for the overall study population, as well as stratified by age group (18-25, 26- 
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HbA1c, % BMI, body mass index; CHD, coronary heart disease; CV, cardiovascular; DBP, diastolic blood pressure; FBG, fasting blood glucose; HbA1c, glycosylated hemoglobin; HDL, highdensity lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; MI, myocardial infarction; PAD, peripheral artery disease; SBP, systolic blood pressure. Table 1 .
HbA1c was 7.8% ( Figure 3) , and more than half of participants had an HbA1c value > 7.5%. Among the entire cohort, 10.4% of people experienced at least one severe hypoglycemia and 5.8% experienced at least one DKA episode during the most recent treatment year ( Figure 3 ). Figure 1) .
Differences between age groups
Median HbA1c was progressively lower in olderage groups (p < 0.01), with values decreasing from 8.1% among 18-25-year olds to 7.5% among those aged > 49 years ( Figure 3 ). The percentage of people with an HbA1c value > 7.5% also decreased across the age groups (p < 0.01). Median FBG did not differ significantly with age. Severe hypoglycemic incidents were progressively more common among older-age groups (Figure 3 ), increasing from 6.2% among those aged 18-25 years to 13.8% among those aged > 49 years (p < 0.01). The frequency of Figure 3 ).
Glucose monitoring
Data on glucose monitoring were available for 46,569 participants using SMBG, 138 using CGM and 614 using FGM (Table 3 ). The median age of people using FGM (19.3 years) and CGM (20.5 years) was significantly lower than that of SMBG users (36.6 years). There was no difference in the proportion of men/ women using the different types of glucose monitoring. FGM users had a slightly shorter duration of diabetes compared with SMBG users (median 10.0 versus 12.6 years, p < 0.01). Median FBG level was lower among FGM (7.9 mmol/l) and CGM (mmol/l) compared with SMBG users (8.3 mmol/l) with only FGM versus SMBG reaching statistical significance (p = 0.02). Median HbA1c levels were also reduced with FGM (7.5%) and CGM (7.5%) versus SMBG (7.8%; p < 0.01). Significantly fewer FGM users (5.7%) than SMBG users (11.3%) experienced severe hypoglycemia, and significantly fewer FGM users (2.6%) experienced DKA episode compared with SMBG users (5.7%; Figure 4 ).
Pump versus MDI populations
Characteristics of patients using a pump (n = 13,652) or MDIs (n = 35,510) are summarized in Table 4 . A larger proportion of the MDI group were men compared with pump users (57.6% versus 44.2%, p < 0.01). The MDI group was older than the pump group (median 37.4 versus 29.0 years, p < 0.01), but MDI users had diabetes for a shorter time than pump users (median 11.1 versus 14.8 years, p < 0.01). MDI users were more likely to be smokers and have a sedentary lifestyle than pump users (p < 0.01). Median FBG was higher in the MDI group than the pump group (8.7 versus 7.8 mmol/l, p < 0.01) ( Figure 5 ). Median HbA1c was 7.9% in the MDI group and 7.7% in the pump group (p < 0.01) and more participants had an HbA1c value > 7.5% (p < 0.01) in the MDI group than the pump group. 
Discussion
This study evaluated the characteristics of a large cohort of 56,250 adults with T1DM and included a comparison of different age groups and a comparison of pump and MDI users. It further explored the balance of benefits (e.g. HbA1c) and risks (hypoglycemia, DKA) of treatment in this patient population. The analyses demonstrated less-than-optimal glycemic control in the young, an increasing metabolic pattern in T1DM with age, a benefit of FGM to improve the balance of HbA1c control and adverse effects such as hypoglycemia and DKA, as well as the benefits of pump treatment over multidose injections.
General characteristics
More than half of the study population were men, which is consistent with previous reports on T1DM. 9, 18, 19 Only 15.3% of participants were obese; median BMI was 24.6 kg/m 2 , which is similar to values reported previously in Europe and the USA. 9, 17, 19 Approximately one quarter of participants were current smokers, and more than half led a sedentary lifestyle, findings which are consistent with other data. 9 It has been shown previously that physical activity has beneficial effects with respect to glycemic control and comorbidities in people with T1DM, suggesting that increased efforts to promote physical activity in people with T1DM may be worthwhile. 20 Increasing age and hyperglycemia (higher HbA1c) have been shown to be the most important risk factors for CV disease in people with T1DM, although other factors such as blood pressure and lipid levels are also relevant. 21 In the current study, more than half of people with T1DM had poor glycemic control, as indicated by an HbA1c value > 7.5%, which is slightly lower than the rate reported for the large T1D Exchange clinic registry in the USA (68%). 17 More than 40% of participants had hypertension, which is higher than the rates reported in small studies in Germany (18.5%) and Europe (28.1%), 9, 19 even though a conservative definition of hypertension was used and estimates would have been higher considering stringent control targets.
Differences between age groups
The current analysis found several differences in patient and disease characteristics between different adult age groups. As might be expected, 21 the prevalence of CV comorbidities (hypertension, PAD, CHD, and a history of MI or stroke) increased with age. CV risk factors, including the rate of obesity, a sedentary lifestyle, and smoking also increased with age, although smoking decreased again in the group aged > 49 years.
Glycemic control, reflected by HbA1c, was better among older-age groups: almost two thirds of the group aged 18-25 years had an HbA1c value > 7.5% compared with less than half of those aged > 49 years. Other studies of adults with T1DM have found that glycemic control tends to improve with increasing age. 17, [22] [23] [24] Episodes of severe hypoglycemia were more common among older people in the current study, a finding that has been reported previously. 17, 22 DKA was less common with increasing age, which has also been reported previously. 17, 25 Insulin therapy was less common in the older-age groups, while the use of adjuvant oral antidiabetic medication increased. The proportion of people using MDIs to administer insulin did not differ substantially between the age groups, whereas older participants (aged > 49 years) were less likely than younger people to be using an insulin pump. The current analysis found that only 16.1% of those aged > 49 years used a pump compared with 25.3-30.7% of younger people. A previous DPV analysis found that only 1.2% of patients aged > 60 years used a pump compared with 23.8% of younger people. 22 This contrasts with the T1DM population in the USA, where pump use did not differ substantially between adult age groups (age 18-25 years, 55%; age 26-49 years, 63%; age ⩾ 50 years, 60%). 17 The reasons for lower pump use among older people in the current study were not identified. The use of metformin and other noninsulin medications increased among older-age groups, which is consistent with data from the USA. 17 With respect to glucose monitoring, use of CGM/FGM was highest (10.4%) in the group aged > 49 years, although the differences between age groups were modest. In the USA, CGM use was higher in the groups aged 26-49 years (23%) and ⩾50 years (18%) than among those aged 18-25 years (7%). 17 Reasons for the increased use of CGM among older patients were not identified, but it is possible it relates to the increased risk of hypoglycemic episodes in this age group.
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Glucose monitoring
Frequent SMBG can help improve glycemic control among people with T1DM. [26] [27] [28] [29] In the current analysis, participants performed testing an average 30 times per week (4.3 times per day), which is slight less but essentially consistent with a previous analysis of the DPV database (5.0 times per day) 29 or for the T1D Exchange registry in the USA (4.7 times per day). 17 CGM/FGM can help reduce HbA1c and blood glucose levels. [30] [31] [32] [33] Only 9.6% of people in the current study were using CGM/FGM. This compares with 11% among participants in the US T1D Exchange registry. 17 The reasons for using CGM/FGM were not identified in the current analysis, but the German Diabetes Association recommends that CGM is indicated for patients with frequent severe hypoglycemic episodes, unsatisfactory metabolic control, or who need more than 10 blood glucose measurements per day to achieve HbA1c target. 31 A previous analysis of the DPV database found that CGM use by adults with T1DM was associated with significantly lower HbA1c values, but not with a reduction in hypoglycemic events. 30, 34 Therapy The use of insulin pumps may have beneficial effects on outcomes compared with the use of MDIs, probably by reducing the risk of hypoglycemic and hyperglycemic episodes. 35 A previous analysis of the DPV database found that use of insulin pumps among adults with T1DM increased from 13.5% in 2002 to 31.5% in 2014. 15 This remained rather stable since, with about one quarter of adults with T1DM (24.1%) using an insulin pump in the current analysis. This is substantially less than the 60% rate reported in the USA (in an analysis which included all ages from 2 years onwards). 17 The current study included a comparison of patient characteristics prior to initiating pump or MDI therapy, which found that people starting pump therapy were younger, but had had diabetes for longer, than MDI users. Pump users were less likely than MDI users to be smokers or to have a sedentary lifestyle and had fewer comorbidities. Prior to initiating therapy, people who subsequently started insulin pump therapy had a lower median FBG level, lower median HbA1c, and were less likely to have poor glycemic control (HbA1c > 7.5%) than those who started MDI therapy. Overall, this indicates that pumps were more likely to be used by younger, healthier people.
The most common noninsulin medication administered to T1DM patients in the current study was metformin, which is consistent with data from the USA. 17 
Strengths and Limitations
Participants were recruited at specialized diabetes-care centers interested in participating in diabetes registries. The cross-sectional nature of the study means that causal links between findings cannot be made. The main strengths of the study are the large number of subjects and the fact they came from a routine clinical practice setting and the study thus provides a picture of current realworld practice.
Conclusion
These data demonstrated less-than-optimal HbA1c-based glycemic control in the young, an increasing metabolic pattern in T1DM with increasing age, a benefit of FGM to improve the balance of HbA1c control and adverse effects such as hypoglycemia and DKA as well as the benefits of pump treatment over multi dose injections.
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